title: Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.
abstract: Current evidence suggests that the genetic risk of breast cancer may be caused primarily by rare variants. However, while classification of protein-truncating mutations as deleterious is relatively straightforward, distinguishing as deleterious or neutral the large number of rare missense variants is a difficult on-going task. In this article, we present one approach to this problem, hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer (CBC) in which all the participants were genotyped for variants in BRCA1 and BRCA2. Hierarchical modeling permits leverage of information from observed correlations of characteristics of groups of variants with case-control status to infer with greater precision the risks of individual rare variants. A total of 181 distinct rare missense variants were identified among the 705 cases with CBC and the 1,398 controls with unilateral breast cancer. The model identified three bioinformatic hierarchical covariates, align-GV, align-GD, and SIFT scores, each of which was modestly associated with risk. Collectively, the 11 variants that were classified as adverse on the basis of all the three bioinformatic predictors demonstrated a stronger risk signal. This group included five of six missense variants that were classified as deleterious at the outset by conventional criteria. The remaining six variants can be considered as plausibly deleterious, and deserving of further investigation (BRCA1 R866C; BRCA2 G1529R, D2665G, W2626C, E2663V, and R3052W). Hierarchical modeling is a strategy that has promise for interpreting the evidence from future association studies that involve sequencing of known or suspected cancer genes.
authors.affiliation: Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Marinela
authors.initials: M
authors.lastname: Capanu
authors.forename: Patrick
authors.initials: P
authors.lastname: Concannon
authors.forename: Robert W
authors.initials: RW
authors.lastname: Haile
authors.forename: Leslie
authors.initials: L
authors.lastname: Bernstein
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Malone
authors.forename: Charles F
authors.initials: CF
authors.lastname: Lynch
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Liang
authors.forename: Sharon N
authors.initials: SN
authors.lastname: Teraoka
authors.forename: Anh T
authors.initials: AT
authors.lastname: Diep
authors.forename: Duncan C
authors.initials: DC
authors.lastname: Thomas
authors.forename: Jonine L
authors.initials: JL
authors.lastname: Bernstein
authors.forename: Colin B
authors.initials: CB
authors.lastname: Begg
mesh_terms: D001499:Bayes Theorem; D001943:Breast Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D014644:Genetic Variation; D006801:Humans; D016013:Likelihood Functions; D008957:Models, Genetic; D015233:Models, Statistical; D020125:Mutation, Missense; D016609:Neoplasms, Second Primary / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors